{"id":1726,"date":"2026-03-29T08:55:00","date_gmt":"2026-03-29T08:55:00","guid":{"rendered":"https:\/\/wickedsister.evit.com.au\/index.php\/2026\/03\/29\/msbase-says-keep-going-with-cd20-depletion\/"},"modified":"2026-03-29T08:55:00","modified_gmt":"2026-03-29T08:55:00","slug":"msbase-says-keep-going-with-cd20-depletion","status":"publish","type":"post","link":"https:\/\/wickedsister.evit.com.au\/index.php\/2026\/03\/29\/msbase-says-keep-going-with-cd20-depletion\/","title":{"rendered":"MSBase says keep going with CD20-depletion"},"content":{"rendered":"<div class=\"twitter-share\"><a href=\"https:\/\/twitter.com\/intent\/tweet?url=https%3A%2F%2Fmultiple-sclerosis-research.org%2F2026%2F03%2Fmsbase-says-keep-going-with-cd20-depletion%2F&#038;via=the_MSBlog\" class=\"twitter-share-button\" data-size=\"large\">Tweet<\/a><\/div>\n<p>Zangh\u00ec A, Spelman T, Fabis-Pedrini M, Carroll WM, Butzkueven H, Kermode AG, Lechner-Scott J, van der Walt A, D&#8217;Amico E. Ocrelizumab Discontinuation vs. Continuation After Safety Events: Comparative Insights from MSBase. Curr Neuropharmacol. 2026 Mar 24. doi: 10.2174\/011570159X448901251228053318.\u00a0<\/p>\n<p><strong>Introduction<\/strong>: Ocrelizumab (OCR), a CD20+ B-cell depleting monoclonal antibody, is a highly effective therapy for Multiple Sclerosis (MS). However, safety concerns may lead to treatment discontinuation, raising questions about the clinical consequences of such decisions.<\/p>\n<p><strong>Materials and methods:\u00a0<\/strong>This propensity score-matched study utilized data from the MSBase registry to compare outcomes between patients discontinuing OCR due to safety concerns (&#8220;<em>Switchers<\/em>&#8220;) and those continuing treatment (&#8220;<em>Continuers<\/em>&#8220;). Matching was performed&#8230;to balance treatment duration and baseline characteristics. Primary outcomes included annualized relapse rate (ARR), time to first relapse, 24-48 weeks confirmed disability worsening (CDW), and progression independent of relapse activity (PIRA).<\/p>\n<p><strong>Results:\u00a0<\/strong>From an initial cohort of 310 Switchers and 1,315 Continuers, 66 patients who experienced at least one safety event and switched from OCR were matched with 66 Continuers&#8230;..<strong>Analyses revealed higher ARR in Switchers (0.08, 95% CI: 0.05-0.14) versus Continuers (0.038, 95% CI: 0.02-0.07; p=0.040)<\/strong>. Time to first relapse showed no significant difference (HR=2.23, 95% CI: 0.68-7.28; p=0.183). Trends toward increased CDW24 weeks risk (PS-IPTW HR=2.11, 95% CI: 0.93-4.75; p=0.073), while no significant difference was found at 48 weeks (HR=1.81, 95% CI: 0.83-3.30; p=0.201). PIRA risk showed a trend toward an increase in Switchers (HR=2.45, 95% CI: 0.95-6.29; p=0.063).<\/p>\n<p><strong>Discussion:\u00a0<\/strong>In this propensity-score-matched analysis, OCR <strong>discontinuation due to safety concerns was associated with increased relapse activity<\/strong> and trends toward greater disability progression. <strong>These findings highlight the importance of maintaining therapeutic intensity<\/strong> and systematic monitoring during treatment transitions to mitigate safety risks <\/p>\n<p>Conclusion: Further research is needed to develop strategies for effectively managing adverse events to optimize patient outcomes.<\/p>\n<p><em>Source: <a href=\"https:\/\/multiple-sclerosis-research.org\/2026\/03\/msbase-says-keep-going-with-cd20-depletion\/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=msbase-says-keep-going-with-cd20-depletion\" rel=\"nofollow noopener\" target=\"_blank\">multiple-sclerosis-research.org<\/a><\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Tweet Zangh\u00ec A, Spelman T, Fabis-Pedrini M, Carroll WM, Butzkueven H, Kermode AG, Lechner-Scott J, van der Walt A, D&#8217;Amico E. Ocrelizumab Discontinuation vs. Continuation After Safety Events: Comparative Insights from MSBase. Curr Neuropharmacol. 2026 Mar 24. doi: 10.2174\/011570159X448901251228053318.\u00a0 Introduction: Ocrelizumab (OCR), a CD20+ B-cell&hellip;<\/p>\n","protected":false},"author":0,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[11,15,9,8,13,14,12,10],"class_list":["post-1726","post","type-post","status-publish","format-standard","hentry","category-multiple-sclerosis-research","tag-brain-repair","tag-marburg-type-ms","tag-ms","tag-multiple-sclerosis","tag-myelin","tag-neuroregeneration","tag-oligodendrocyte","tag-remyelination"],"_links":{"self":[{"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/posts\/1726","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/comments?post=1726"}],"version-history":[{"count":0,"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/posts\/1726\/revisions"}],"wp:attachment":[{"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/media?parent=1726"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/categories?post=1726"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/tags?post=1726"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}